Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Collegium Pharma (NQ: COLL )

35.01 +0.24 (+0.69%)
Streaming Delayed Price Updated: 9:46 AM EDT, Apr 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 13,532
Open 34.65
Bid (Size) 34.92 (4)
Ask (Size) 35.11 (4)
Prev. Close 34.77
Today's Range 34.58 - 35.05
52wk Range 20.83 - 40.95
Shares Outstanding 31,959,828
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Critical Insights From Collegium Pharmaceutical Analyst Ratings: What You Need To Know
Via Benzinga
Collegium Pharmaceutical, Inc. Announces Redemption of Outstanding 2.625% Convertible Senior Notes Due 2026
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire

Performance

YTD
+12.10%
+12.10%
1 Month
-7.77%
-7.77%
3 Month
+6.51%
+6.51%
6 Month
+65.22%
+65.22%
1 Year
+53.02%
+53.02%

More News

Read More
Collegium to Participate in 23rd Annual Needham Virtual Healthcare Conference
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Where Collegium Pharmaceutical Stands With Analysts
Via Benzinga
Recap: Collegium Pharmaceutical Q4 Earnings
Via Benzinga
Analyst Expectations For Collegium Pharmaceutical's Future
Via Benzinga
Why Collegium Pharmaceutical Shares Are Gaining Today
Via Benzinga
Collegium Reports Record Fourth Quarter and Full-Year 2023 Financial Results
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Collegium to Report Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
TDCX Receives Preliminary Non-binding Proposal Letter, Joins Pure Storage, Dyne Therapeutics And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Topics Stocks
Exposures US Equities
Recap: Collegium Pharmaceutical Q3 Earnings
Via Benzinga
Needham Maintains Buy Rating for Collegium Pharmaceutical: Here's What You Need To Know
Via Benzinga
Collegium Provides 2024 Financial Guidance
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Appeals Court Upholds PTAB’s Finding of Invalidity of Purdue’s 961 Patent
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Collegium Announces $25 Million Accelerated Share Repurchase Program
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Collegium to Participate in Upcoming Investor Conferences
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Collegium Reports Third Quarter 2023 Financial Results
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Collegium to Report Third Quarter 2023 Financial Results on November 7, 2023
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Collegium Announces 10 Poster Presentations at PAINWeek Conference 2023
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Collegium Announces Extension of Nucynta Regulatory Exclusivity through July 2026
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Collegium Announces $50 Million Accelerated Share Repurchase Program
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Atlassian, Universal Display, Booking, Dropbox And Other Big Stocks Moving Higher On Friday
Via Benzinga
Collegium Reports Record 1H’23 Net Revenue of $280.3 Million, Up 35% Year-over-Year
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Collegium to Report Second Quarter 2023 Financial Results on August 3, 2023
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Collegium to Participate in Jefferies Healthcare Conference
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.